Genetic and Cellular Therapies
Linas JuozėnasShare
Genetic & Cellular Therapies
The ability to change a cell’s instructions or support tissue repair is opening important possibilities in medicine. The meaningful outcome is what those changes allow a person to do.
For someone living with a serious inherited disorder, a treatment may address a biological cause that exercise cannot correct. For someone recovering from an injury, the goal may be less pain, useful movement or a durable return to a valued activity.
This guide explores the science behind gene therapy, genome editing and cell-based repair—and how to distinguish established applications, promising research and claims that run ahead of the evidence.
A gene transfer, a genome edit and a mixed cell preparation are different treatments.
More muscle, a changed scan, less pain and improved movement are distinct outcomes.
Assessment, treatment quality, rehabilitation and follow-up belong together.
Repair, muscle growth and physical function
Regenerative medicine explores ways to repair, replace or support damaged cells and tissues. Gene-based therapies aim to change the genetic information available to cells or how that information is used. Cell therapies use living cells as part of the treatment. These fields overlap, but they are not interchangeable.
A person’s own cells can be genetically modified outside the body and then returned. Another treatment may deliver genetic material directly into the body. A third may implant cells without changing their DNA. The label “advanced therapy” does not tell us which of these is happening.
Define success before discussing the technology
For muscle disease, success might mean preserving a valued ability, slowing loss of function or making everyday tasks less demanding. For an injury, it might mean restoring stability, tolerating a chosen activity or reducing symptoms. For research on muscle growth, it might initially mean a measurable biological change.
These goals require different assessments. A larger muscle does not automatically produce a proportionate increase in strength. A stronger isolated muscle does not by itself establish better balance, endurance or coordinated movement. Similarly, a change on an image does not tell us everything about pain or participation.
Biological effect
Did the intervention alter the intended gene, protein, cell activity or tissue feature?
Functional effect
Did a relevant ability improve or remain stable compared with an appropriate alternative?
Value in everyday life
Was the change meaningful, durable and worth the treatment’s burdens for that person?
The strongest promise of this field is the possibility of addressing problems for which existing care is incomplete. Evaluating that promise carefully respects both scientific progress and the people who may depend on it.
Throughout this guide, keep one question in view: Which treatment, for which condition, has shown which benefit? It is more informative than asking whether “stem cells work” or whether “gene therapy is the future.”
Gene therapy, gene editing and gene regulation
A gene is a region of DNA whose information contributes to a functional product, often a protein. Gene expression is the process through which that information is used. A treatment may add instructions, alter existing DNA or change the production of a gene’s product.
These distinctions matter because the mechanism influences delivery, duration, possible unwanted effects and the questions a clinical study must answer.
| Approach | What changes | Important distinction |
|---|---|---|
| Gene addition or transfer | Introduces genetic material that cells can use to make a therapeutic product. | It need not repair or remove the original DNA variant. |
| Genome editing | Alters a selected DNA sequence. | The intended edit and any unintended changes require evaluation. |
| Gene regulation or silencing | Changes the activity or output of a gene through a defined mechanism. | Some methods act without changing the underlying DNA sequence. |
| Ex vivo modification | Cells are collected and modified outside the body before administration. | The cells and the complete manufacturing process are part of the treatment. |
| In vivo delivery | The therapeutic material is administered directly into the body. | Reaching the right cells and limiting unwanted exposure become central challenges. |
How CRISPR-based editing fits in
The foundational CRISPR-Cas9 work demonstrated an RNA-guided system for cutting selected DNA.[1] A guide RNA directs the machinery toward a target; it is not, by itself, a universal replacement template. The eventual genetic change also depends on the editing design and the cell’s response.
Some editing approaches create a break in both DNA strands. Repair can disrupt a gene or, under suitable conditions, incorporate a desired change. A cut does not guarantee that every treated cell will acquire the intended sequence.
Base editing was developed to make selected single-letter DNA changes without requiring a double-strand break.[2] Prime editing combines a modified targeting system with a template-bearing guide and an enzyme that writes DNA information, allowing a different range of changes.[3]
These methods expand the research toolkit. They do not make delivery, unwanted editing, manufacturing quality or long-term follow-up irrelevant. Older tools, including zinc-finger nucleases and TALENs, also belong to the broader history of targeted genome modification.
For a reader, the practical distinction is simple: a headline about a “gene therapy” does not establish that CRISPR was used, that a disease-causing variant was corrected, or that the result applies to muscle enhancement.
Delivery, distribution and durability
Identifying a useful biological target is an important achievement. A treatment must then reach enough of the relevant cells, produce the intended effect and avoid unacceptable consequences elsewhere.
Muscle presents a substantial delivery challenge. Skeletal muscles are distributed throughout the body, muscle fibres are large and contain many nuclei, and some disorders also affect breathing or the heart. A local experiment in one muscle cannot establish effective treatment of a whole-body disease.
What is a vector?
A vector carries genetic material into cells. Some therapies use modified viruses; others use non-viral approaches. The carrier, the therapeutic material and the route of administration all influence where exposure occurs.
Adeno-associated virus, or AAV, is one vector platform used in gene therapy. Using a viral vector does not make a treatment a vaccine. Its purpose may be to deliver instructions for a therapeutic protein rather than to prepare immunity against an infection.
Immune responses to the carrier or expressed product can matter. So can unintended exposure, the amount of genetic material reaching cells and the ability to administer treatment again. These questions cannot be settled by the claim that a carrier is “natural” or a gene is “human.”
Precision includes the outcome in the cell
Genome-editing assessment examines unintended changes both away from the target and at the intended site. FDA guidance addresses product quality, delivery and the characterisation of genome-editing outcomes.[4] A molecular tool can be highly targeted while still requiring careful assessment of the final biological result.
Duration also varies. Some effects may persist for years, whereas other approaches are temporary or affected by cell turnover. “Permanent” is not a synonym for complete, controllable or clinically beneficial.
Long-term follow-up is planned according to the particular product and its risks. FDA guidance describes how delayed effects may require observation beyond the initial treatment period.[5] This is part of developing dependable medicine, especially when an intervention cannot simply be stopped like a daily tablet.
Ask what is known about distribution, persistence and repeat treatment for the exact product. Those details often matter more than the name of the editing platform.
Myostatin and the pursuit of muscle growth
Myostatin, encoded by the MSTN gene, is a signalling protein involved in limiting skeletal muscle growth. Its biology has attracted interest in conditions associated with muscle loss, as well as speculation about athletic enhancement.
A 2004 report described a child with a myostatin gene mutation and unusually pronounced muscle development.[6] Such observations help reveal a pathway’s biological role. They do not establish the long-term consequences of deliberately changing that pathway in an adult.
A pathway can be targeted in different ways
Researchers can investigate gene-based approaches, antibodies or other molecules that affect signalling. Blocking a receptor with a medicine is not the same intervention as editing MSTN. Some targets also participate in signalling from more than one protein.
Bimagrumab illustrates why the endpoint matters. It is an antibody targeting activin type II receptors, not a genome-editing treatment. In a trial involving older adults recovering from hip fracture, it increased lean body mass, but improvements in walking speed and a physical performance test battery were not significantly different from placebo.[7]
This finding does not rule out every future application of the pathway. It shows that a biological gain needs to be connected to the functional benefit being promised.
The rest of the movement system still matters
Useful force depends on more than muscle quantity: the task also involves nervous-system control, muscle architecture, tendon force transmission, joint movement and practice. Endurance introduces further demands on energy supply and sustained work.
It is therefore premature to assume that increasing muscle growth would automatically improve tendon resilience, protect joints or allow a person to tolerate any training load. Those are separate claims requiring their own evidence.
For muscle-wasting conditions, preserving a meaningful ability may be more valuable than a striking change in appearance. For sport, an intervention also has to be considered within anti-doping rules. Neither context is served well by describing a signalling pathway as a simple “strength switch.”
Beyond myostatin: other biological pathways
Muscle adaptation draws on many interacting signals. Changing one part of the system can be informative in research without producing a complete or predictable enhancement of human performance.
Follistatin
Follistatin binds members of a family of signalling proteins that includes activins and myostatin. Researchers have explored gene transfer designed to increase follistatin production. A small phase 1/2a study in six people with Becker muscular dystrophy provided early clinical observations.[8]
That study was not a trial in healthy athletes and did not establish a general enhancement treatment. Its small size and early design limit conclusions about effectiveness, uncommon harms and durability. It also concerned gene transfer, which should not be retold as successful CRISPR editing.
PPAR-delta and endurance-related biology
PPAR-delta is involved in the regulation of metabolic processes. Experiments in genetically modified mice demonstrated changes in muscle fibre characteristics and running endurance.[9] These findings help investigate how metabolism and performance are connected.
A result in a mouse does not establish a safe or effective intervention for human endurance. The species, experimental modification, activity test and duration of observation all limit the inference.
IGF-1 and local growth signalling
Insulin-like growth factor 1 participates in growth-related signalling. Research using local Igf-1 transgene expression in mice explored muscle growth and regeneration during ageing.[10] This is a preclinical example of how tissue-specific signalling can be studied.
Increasing a signal in a particular experimental setting is different from safely controlling it across a person’s body. Timing, location and the wider effects of a pathway matter alongside the desired response.
Genetics does not provide a complete training script
A clearly diagnosed inherited disease and a commercial “fitness genes” report answer very different questions. A test result does not, by itself, specify the best exercise programme, predict the next injury or identify a gene that should be changed.
For ordinary training decisions, actual performance, symptoms, experience and circumstances remain relevant. Genetic information may have a medical role when interpreted for a specific question; it should not become a fixed judgment about someone’s potential.
What clinical gene therapy has shown
Gene-based medicine has moved beyond a purely theoretical idea. Its established applications are specific, however, and the demands of treating a serious disease differ from those of enhancing an otherwise healthy person.
Casgevy: an example of gene editing in medicine
In the EU, Casgevy has conditional authorisation for selected patients aged 12 and older with transfusion-dependent beta thalassaemia or severe sickle cell disease. Eligibility also depends on suitability for stem-cell transplantation and the absence of a matched related donor.[11]
The patient’s blood-forming stem cells are edited outside the body to increase fetal haemoglobin production. Treatment includes conditioning chemotherapy before the modified cells are administered. It is a specialist pathway for particular blood disorders, not a fitness intervention or an injection that edits every tissue.
Elevidys: gene transfer for a muscle disease
Elevidys uses an AAV vector to deliver instructions for a shortened dystrophin protein. It is a gene-transfer therapy rather than CRISPR correction of the underlying DMD variant.
As checked on 6 September 2026, the FDA indication is for ambulatory patients aged four years and older with Duchenne muscular dystrophy and a confirmed DMD mutation. Its safety information includes a boxed warning for acute serious liver injury and acute liver failure.[12]
The EMA’s public record reports a recommendation to refuse marketing authorisation, issued in July 2025.[13] Regulatory assessments and permitted uses can differ between jurisdictions and can change with new evidence.
What these examples establish
They demonstrate why we need to name the product, mechanism, condition and regulatory setting. An authorised treatment for one disease does not validate a different product sold for recovery, ageing or athletic performance.
They also show why treatment involves more than administering a biological material. Selection, preparation, specialist services and monitoring are part of the intervention. Benefits and burdens have to be understood together.
The important lesson is that the field contains real medicine and unresolved questions at the same time. Progress in one carefully defined application is a reason to investigate further applications properly, with outcomes that matter to the people being treated.
Stem cells, progenitor cells and specialised cells
A stem cell can renew itself and produce more specialised descendants. Its potential depends on the type of stem cell and its biological environment. The term does not mean that any cell can become any tissue after injection.
Pluripotent stem cells can give rise to the major cell types of the body under appropriate conditions. Embryonic stem cells and induced pluripotent stem cells belong to this broad category. The latter are produced by reprogramming specialised cells.[14]
Adult, or tissue-resident, stem cells generally have a more restricted role. Blood-forming stem cells produce blood lineages. Muscle satellite cells support skeletal muscle repair. A progenitor cell is a related term for a cell with a capacity to produce particular descendants, often with more limited self-renewal.
The intended cell product may already be specialised
A therapy developed using pluripotent cells may administer carefully differentiated descendants rather than undifferentiated stem cells. A cartilage treatment may use the patient’s own chondrocytes, the specialised cells that produce cartilage matrix.
This makes cell identity and purity important. The desired cells, unwanted cells, their state of maturation and what they can do all belong in the description of the product. A large cell count alone cannot answer those questions.
What does “MSC” mean?
The abbreviation MSC is often used for mesenchymal stromal cells. The International Society for Cell & Gene Therapy recommends precise terminology and evidence when making claims of stemness.[15] A preparation’s ability to meet laboratory criteria does not show that it will reconstruct a damaged joint after injection.
Researchers investigate several possible actions, including interactions with immune cells and the release of signalling molecules. Directly replacing damaged tissue is only one proposed route to benefit, and it should not be assumed without evidence.
There are authorised MSC medicines for specific conditions. For example, the FDA approved Ryoncil, a donor bone-marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in eligible children.[16] That is a distinct indication following transplantation, not evidence for routine sports-injury injections.
The useful question is: What are these cells, what are they expected to do, and what has this exact product shown?
Understanding injections and cell preparations
“Stem-cell treatment” is sometimes used to describe products that differ greatly in source, processing, composition and intended action. Before comparing results, establish what was actually administered.
Autologous means obtained from the same person who receives the treatment. Allogeneic means obtained from a donor of the same species. These terms describe origin; neither establishes effectiveness or eliminates the need for quality control.
| Preparation | What it contains or involves | What should not be assumed |
|---|---|---|
| Bone marrow aspirate concentrate, or BMAC | A concentrated mixture obtained from bone marrow, containing several cell populations and other components. | It is not a purified, uniform population of stem cells. |
| Adipose-derived preparations | Products obtained from fat tissue; processing may yield different cell or tissue mixtures. | Stromal vascular fraction, processed tissue and expanded cells are not interchangeable. |
| Culture-expanded stromal cells | Selected cells multiplied under controlled manufacturing conditions. | Results from one source and process do not automatically apply to another. |
| Chondrocyte implantation | Cartilage cells prepared for placement into a selected defect. | An established cartilage-cell procedure is not proof for general stem-cell injections. |
| Platelet-rich plasma, or PRP | A blood preparation enriched in platelets. | It is not a stem-cell therapy or a gene-editing treatment. |
| Extracellular-vesicle preparations | Particles released by cells, investigated for their cargo and signalling actions. | They are not living stem cells, and “exosome” does not establish a proven repair treatment. |
AAOS describes orthobiologics as a broad group that includes different cell, tissue and blood-based approaches.[17] Their evidence should be assessed separately rather than combined under one reassuring label.
Exosomes require their own evidence
Extracellular vesicles are membrane-enclosed particles released by cells. Exosomes are a particular category associated with a specific cellular origin; the term should not be used as a substitute for properly characterising a product. The MISEV2023 guidance addresses the identification and study of extracellular vesicles.[18]
The possibility that vesicles carry useful signals does not establish that a marketed preparation contains the claimed material, reaches the target or improves an injury. Removing living cells from a preparation does not remove all questions about contamination, biological activity or unintended effects.
Processing is part of the intervention
Collection, separation, expansion, storage and administration can change a preparation. Ask whether the treatment being offered matches the product used in the cited study. A shared tissue source is not enough.
A useful written description includes the exact product, source, processing and intended clinical use. If the explanation stays at “millions of healing cells,” it has not yet supplied the information needed for a meaningful comparison.
Cell-based repair of cartilage defects
Articular cartilage provides a specialised surface where bones meet in a joint. A focal cartilage defect is a local area of damage. Osteoarthritis involves a wider joint disorder and cannot be treated as simply the same problem with a larger hole.
That distinction matters when interpreting cell-based cartilage procedures. The location and extent of damage, symptoms and the condition of the rest of the joint influence the clinical question.
An authorised example in the EU
Spherox contains spheroids made from the patient’s own chondrocytes. In the EU it is authorised for selected symptomatic knee-cartilage defects up to 10 cm² in adults and adolescents whose joint bones have finished growing. It must not be used for primary generalised osteoarthritis or advanced knee osteoarthritis.[19]
Cells are prepared from a cartilage sample and implanted into the defect through a specialist procedure. A defined rehabilitation programme is part of treatment. This is a specific cartilage-cell medicine, not a general stem-cell injection for any painful knee.
Match the proposed treatment to the diagnosis
For someone considering a cartilage procedure, the first discussion should concern the actual problem: where the defect is, whether it explains the symptoms, what other joint factors matter and which options are reasonable.
Useful questions include what improvement is expected in everyday activities, what the recovery process involves, how progress will be assessed and what the plan is if the result is incomplete. These questions help connect a technically successful procedure with the person’s reasons for considering it.
The existence of a validated treatment for a defined defect is encouraging. It also shows why precise selection is important. We should preserve that specificity when explaining the science to a wider audience.
Cell injections for knee osteoarthritis
Many people with knee osteoarthritis are interested in treatments that might reduce pain or preserve activity. Those are meaningful goals. Claims of rebuilding cartilage or reversing the disease require additional evidence beyond a change in symptoms.
What a larger comparative trial found
The MILES trial randomised 480 participants and compared three cell-based preparations with corticosteroid injection. At one year, none of the cell-treatment groups showed significantly better improvement in the primary pain outcomes than the corticosteroid group. MRI scores also did not demonstrate significant structural improvement.[20]
This result applies to the preparations and comparison studied. It does not establish that every future cell product must fail, nor does improvement within a group show that the added treatment caused all of that improvement.
What the broader evidence suggests
A 2025 Cochrane review found low-certainty evidence that stem-cell injections may slightly improve pain and function compared with placebo. Effects on disease progression and important harms remained uncertain.[21] The review’s evidence search ended in September 2023, an important distinction from its publication date.
These findings address different comparisons and products. Taken together, they do not justify presenting cell injections as established whole-joint regeneration or guaranteed avoidance of future surgery.
| Outcome | What it can help assess | What else may need to be measured |
|---|---|---|
| Pain and symptom scores | How the person feels during daily life or selected activities. | Function, durability, adverse effects and whether improvement exceeds an appropriate comparison. |
| Imaging or tissue measurements | Selected structural features under a defined measurement method. | Whether the change is clinically meaningful and connected to the person’s goals. |
| Strength or movement tests | Performance on a specified task under test conditions. | Everyday participation, sustained use and the demands of the intended activity. |
| Return to sport or work | Whether the person resumes a defined activity. | At what level, for how long, with what symptoms and with what recurrence or reinjury burden. |
Small trials can miss uncommon harms. Different cell sources, processing methods and outcome measures can also make results difficult to combine. A positive study of one preparation should not become a recommendation for every treatment sold under a similar name.
When discussing an injection, ask for the expected additional benefit over appropriate care, the uncertainty around that estimate and whether the goal is symptom management or structural repair. An honest answer may be narrower than the advertisement and more useful for making a decision.
Tendons, ligaments and skeletal muscle
Tendons transmit force between muscle and bone. Ligaments contribute to joint stability. Skeletal muscle produces force through specialised fibres controlled by the nervous system. Repairing these structures involves different biological and mechanical problems.
A treatment that changes inflammation in a joint cannot automatically be assumed to restore a tendon’s attachment, reconstruct a ligament or replace a substantial volume of muscle.
A useful distinction from rotator-cuff research
A randomised trial of 91 people undergoing repair of selected supraspinatus tendon tears examined the addition of concentrated bone marrow aspirate. Among those completing one-year MRI, the supplemented group had fewer imaging-defined retears. The study did not establish corresponding superiority in patient-reported clinical outcomes or treatment-failure rates over the follow-up studied.[22]
This is a promising structural finding within a specific surgical treatment. It is not evidence that an injection alone repairs every tendon tear or allows a faster return to sport.
Muscle has its own repair cells
Satellite cells are tissue-resident stem cells associated with skeletal muscle fibres. Experiments in mice demonstrated their essential role in regeneration after muscle injury.[23] Understanding these cells is an important part of developing muscle-repair strategies.
Using that knowledge therapeutically requires more than placing cells near a damaged area. Researchers need to consider survival, integration, blood supply, nerve connections and the organisation required to transmit force. Large muscle loss presents a different challenge from a smaller injury that can heal through existing repair processes.
Injections, scaffolds and surgical integration
Cells or other biological materials may be delivered locally, placed on a scaffold or incorporated into a surgical procedure. A scaffold can provide structure or help hold material in place. Its composition, degradation and interaction with surrounding tissue are part of the intervention.
Image guidance can help a clinician place a preparation at an intended location. It does not, by itself, establish that the material is effective. Accurate placement and clinical benefit are separate achievements.
For tendon, ligament and muscle injuries, ask whether the research studied the same tissue, diagnosis, treatment combination and recovery goal. An animal experiment, an uncontrolled case series and a comparative human trial contribute different levels of information.
Recovery should be assessed through relevant function and activity tolerance as well as structural findings. A promising scan can guide further investigation while leaving important questions about durable participation unresolved.
Safety, rehabilitation and long-term care
Genetic and cellular therapies are not a single risk category. The relevant risks depend on the product, how it is made, the route of administration and the person’s condition.
Possible problems include infection or contamination, immune reactions, unwanted tissue formation and unintended genetic effects. Some interventions also require surgery, medicines that alter immune activity or preparatory treatment with substantial risks of its own. These should be explained in relation to the actual product, rather than presented as inevitable consequences of every cell therapy.
“From my own body” does not mean risk-free
Autologous cells may avoid some donor-related questions, but collection and processing can still introduce problems. A cell may also behave differently after expansion or after being placed in a different environment.
The ISSCR’s patient guidance emphasises evaluating the exact treatment, the evidence and the safeguards around it.[24] The origin of a material is one detail in that assessment; it is not a complete safety argument.
Rehabilitation remains part of recovery
A biological intervention may change what a tissue can do, but a person still needs to use the recovering system in a suitable way. Strength, movement skill, confidence and activity tolerance may require a planned progression.
The appropriate rehabilitation depends on the procedure and condition. A treatment-specific restriction should not be replaced by a generic internet exercise schedule. Conversely, recovery should include a clear discussion of what remains possible, so the person can participate in suitable activities while protecting the treated area.
For someone planning a procedure, the practical questions are concrete: who provides follow-up, what assistance is needed at home, when work or travel may be practical, and which criteria guide changes in activity? These are examples of planning questions, not a universal rehabilitation timetable.
Track the result that motivated treatment
Before treatment, identify a small number of meaningful outcomes. These might include a particular daily task, symptom burden, walking tolerance or a condition-specific functional measure selected with the care team.
Review progress against that starting point and the expected recovery course. Record complications and additional care as well as benefits. A procedure may improve one outcome while leaving another unchanged; recognising that makes future decisions clearer.
Good care also includes a plan for an incomplete response. The person should know whom to contact, when reassessment is appropriate and which further options remain. Follow-up is part of the treatment’s value, not an optional extra after the biological material has been administered.
Research, regulation, access and sport
Responsible development connects scientific evidence with manufacturing quality, clinical oversight and the ability to learn from results. These arrangements help turn a promising mechanism into a dependable treatment.
Understand the status being claimed
In the EU, advanced therapy medicinal products have defined routes for lawful supply, including central authorisation, an authorised clinical trial or a relevant national exemption. EMA and the Heads of Medicines Agencies advise checking the product’s status and intended use with official sources.[25]
An exemption is not the same as EU-wide marketing authorisation. A clinic licence, a published trial registration or a claim of laboratory accreditation does not independently establish that a particular treatment is approved or effective for the proposed condition.
For a study, ask for its identifying number, authorisation, eligibility criteria and responsible institution. Registration makes a study easier to identify; it does not guarantee a favourable outcome.
Consent includes a real choice
A person should understand the proposed benefit, uncertainty, alternatives, follow-up and costs. The freedom to ask questions or seek another opinion matters, especially when a treatment is presented as a last opportunity.
Access also involves more than the price of the product. Travel, time away from work, caring responsibilities, rehabilitation and continuing specialist support can determine whether a treatment is practically available.
Somatic interventions target the treated person’s body cells. Heritable editing raises additional questions because changes could be passed to future generations. These should not be confused with ordinary discussion of a somatic therapy for an existing patient.
Therapeutic use and anti-doping rules
The 2026 WADA Prohibited List includes gene- and cell-based methods with the potential to enhance sport performance under M3. The exact method and any accompanying substances matter.[26]
WADA also states that certain uses of non-transformed stem cells alone to restore normal function after injury are not prohibited under its specified conditions. It is therefore inaccurate to say that every stem-cell treatment is automatically banned.
Athletes subject to anti-doping rules should have the complete proposed treatment checked through the relevant anti-doping organisation before proceeding, including whether a therapeutic use exemption is needed. Medical appropriateness, regulatory status and sporting permission are separate assessments.
Fairness in sport should be discussed without treating people who need medical care as morally suspect. The aim is to support legitimate treatment, informed choice and clear competition rules while evaluating enhancement claims honestly.
A practical framework for evaluating an offer
If a clinic, study or news story raises your interest, start by turning the broad claim into a specific question. The following framework is an original decision aid for discussion with qualified professionals. It is not a method for selecting or carrying out an experimental treatment on your own.
-
Clarify the problem and the goal
Establish the diagnosis and the ability or symptom you want to improve. Ask whether the proposed intervention addresses that problem and what reasonable alternatives exist.
-
Identify the exact treatment
Obtain its name, composition, source and intended mechanism in writing. Distinguish the cells or genetic material from accompanying surgery, medicines and rehabilitation.
-
Examine the matching evidence
Look for studies of that product in people with a similar condition. Check the comparison, relevant outcomes, duration of follow-up, harms and how many participants completed assessment.
-
Understand oversight and practical demands
Verify the applicable regulatory or research pathway. Discuss treatment-specific risks, consent, follow-up, recovery arrangements and the complete cost, including care if problems occur.
-
Make a considered decision and review the result
Take time for questions and an independent opinion where useful. If treatment proceeds, agree how its benefit and burdens will be assessed and who remains responsible for follow-up.
| Question | What a useful answer should explain | What still needs clarification |
|---|---|---|
| What exactly will I receive? | The defined product, source, preparation and accompanying treatment. | A generic label such as “regenerative injection” or “healing cells.” |
| What benefit has been demonstrated? | A relevant outcome in a comparable population, with an appropriate comparison. | Testimonials or before-and-after images presented as sufficient proof. |
| Does the evidence show regeneration? | The structural and functional evidence supporting that particular claim. | Pain relief described as complete restoration of a tissue. |
| What is its legal or research status? | The named authorisation, trial or applicable national pathway. | “Registered” or “approved laboratory” without the product’s actual status. |
| What are the complete burdens? | Risks, preparatory care, rehabilitation, time and follow-up costs. | Only the price of the injection or procedure. |
| Who supports me afterwards? | A responsible care team, review plan and access to help with complications. | A short visit with no clear continuing care arrangement. |
What meaningful progress could look like
Researchers are exploring more selective delivery, improved control over gene activity, better-defined cell products and tissue-engineering approaches that support integration. Combining genetic correction with carefully selected cells may be useful for some conditions.
For larger tissue reconstruction, progress also depends on organisation: cells need an appropriate environment, and functioning tissue may require blood supply, nerve connections and suitable mechanical properties. A larger number of cells is not a substitute for that structure.
Future advances should be judged through more than laboratory performance. Important achievements include a treatment that works reliably across appropriate patients, a simpler care pathway, a durable improvement in function or wider access to a therapy whose benefits are established.
There is no dependable timetable for routine genetic enhancement of healthy athletes or universal regeneration of injured tissues. The field can still make substantial progress through specific treatments that preserve or restore meaningful abilities.
Common questions
Are gene therapy and CRISPR the same thing?
No. Gene therapy includes approaches such as adding genetic material or modifying cells. CRISPR is a family of tools that can support editing or regulation. A gene-transfer treatment may supply instructions for a protein without correcting the original DNA variant.
Does turning down myostatin guarantee greater strength?
No. Myostatin biology is relevant to muscle growth, but muscle quantity, strength and everyday function are different outcomes. Effects also depend on how the pathway is targeted and in whom. Clinical benefit needs direct evaluation.
Can a gene therapy approved for a serious disease be used as evidence for sports enhancement?
Approval concerns a particular product, indication and treatment pathway. It does not establish that another intervention is appropriate for healthy athletes. The expected benefit, tolerance of risk and applicable sporting rules also differ.
Are all stem cells able to become any tissue?
No. Different stem cells have different developmental potential. Tissue-resident stem cells generally have restricted roles. Even pluripotent cells require carefully controlled differentiation and product assessment; they do not automatically create useful tissue after administration.
Is PRP a stem-cell treatment?
No. PRP is a preparation enriched in platelets from blood. It is distinct from stem cells, concentrated marrow, expanded stromal cells and gene therapy. Evidence for one preparation should not be transferred automatically to another.
Are cells from my own body automatically safe?
No. Origin is only one consideration. Collection, processing, contamination, administration and behaviour in the receiving tissue can all matter. Safety has to be assessed for the actual intervention.
Do stem-cell injections regrow knee cartilage?
The evidence does not support a blanket claim of cartilage regrowth or reversal of knee osteoarthritis. Selected cartilage-cell implantation procedures address particular defects and are different from general injections marketed for arthritis.
Can biological treatment let me skip rehabilitation?
A suitable rehabilitation and follow-up plan remains part of many treatment pathways. The appropriate activities and progression depend on the condition and procedure. Ask for that plan before deciding about treatment.
Is every cell treatment prohibited in sport?
No. Rules depend on the exact intervention and circumstances. WADA distinguishes some injury-healing uses from prohibited enhancement methods. Athletes should verify the entire treatment, including added substances and any exemption requirements, with the relevant anti-doping organisation.
What is the most useful question to ask a provider?
Ask what this exact treatment has shown for people with your condition, compared with an appropriate alternative, and whether the benefit concerns symptoms, tissue structure or meaningful function. Then ask about risks, oversight and continuing care.
Sources and further reading
Sources checked 6 September 2026. This guide combines selected original laboratory and clinical studies, an evidence review, professional guidance and official regulatory information. It is an educational overview, not an exhaustive review or an individual treatment recommendation.
Animal experiments explain biological possibilities; they do not establish human treatment outcomes. Early clinical studies, comparative trials and regulatory assessments answer different questions. Findings remain attached to the product, population, condition and outcome studied.
The consultation framework and everyday examples are original practical illustrations. Product indications, trial status and sporting rules may change. The linked records allow readers to check the basis and limits of claims, particularly before making a clinical or sporting decision.
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821.Foundational molecular research on RNA-guided DNA cleavage; not a human muscle-enhancement trial. Return to text ↑
- Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420–424.Original base-editing research. A tool’s molecular capabilities do not establish the clinical suitability of a proposed application. Return to text ↑
- Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–157.Original prime-editing research; a description of an editing approach, not evidence of safe athletic enhancement. Return to text ↑
- US Food and Drug Administration. Human Gene Therapy Products Incorporating Human Genome Editing. Guidance for Industry. January 2024.Official guidance addressing quality and assessment of somatic genome-editing products. Used for general development principles, not as a statement of EU law. Return to text ↑
- US Food and Drug Administration. Long Term Follow-Up After Administration of Human Gene Therapy Products. Guidance for Industry. January 2020.Follow-up depends on product-specific risks and potential delayed effects. Not every intervention requires the same observation period. Return to text ↑
- Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. New England Journal of Medicine. 2004;350:2682–2688.Rare human genetic observation. It does not establish the outcome of deliberately modifying the pathway in healthy adults. Return to text ↑
- Hofbauer LC, Witvrouw R, Varga Z, et al. Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial. The Lancet Healthy Longevity. 2021;2(5):e263–e274.An activin-receptor antibody trial, not gene editing. Lean-mass gains did not establish superior recovery on the reported physical performance outcomes. Return to text ↑
- Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Molecular Therapy. 2015;23(1):192–201.Early gene-transfer study in six participants with Becker muscular dystrophy. Limited evidence for broad efficacy, uncommon harms or healthy-athlete use. Return to text ↑
- Wang Y-X, Zhang C-L, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARδ. PLOS Biology. 2004;2(10):e294.Mouse experiments exploring metabolic regulation and endurance. Not clinical evidence for human enhancement. Return to text ↑
- Musarò A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genetics. 2001;27(2):195–200.Preclinical mouse research using a defined local-expression approach; not a human recovery protocol. Return to text ↑
- European Medicines Agency. Casgevy: European public assessment report and product information. Current product record; checked 6 September 2026.Conditional EU authorisation for defined blood-disorder indications. Eligibility, conditioning and follow-up are integral to the treatment pathway. Return to text ↑
- US Food and Drug Administration. Elevidys: indication, product information and safety updates. Current product record; checked 6 September 2026.US gene-transfer product record, including restricted indication and liver safety warning. Does not describe EU authorisation or a CRISPR therapy. Return to text ↑
- European Medicines Agency. Elevidys: refusal of marketing authorisation. Opinion issued 24 July 2025; public record checked 6 September 2026.Official account of the EMA recommendation. Regulatory assessments are jurisdiction- and date-specific. Return to text ↑
- US National Institutes of Health. Stem Cell Basics. Stem Cell Information.Background on self-renewal, differentiation and types of stem cells. These properties do not guarantee tissue regeneration after administration. Return to text ↑
- Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019–1024.Professional position statement on precise cell terminology and evidence for stem-cell properties; not endorsement of every MSC preparation. Return to text ↑
- US Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. Approval announcement. 18 December 2024.Specific donor-derived MSC therapy for eligible paediatric patients aged two months and older. This approval is not for sports-injury repair. Return to text ↑
- American Academy of Orthopaedic Surgeons. Orthobiologics (Regenerative Medicine) FAQ. OrthoInfo; accessed 6 September 2026.Professional patient information describing the broad category and its different preparations. Evidence and indications vary. Return to text ↑
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles. 2024;13:e12404.Research guidance on identifying and characterising extracellular vesicles. Not clinical validation of commercial exosome injections. Return to text ↑
- European Medicines Agency. Spherox: European public assessment report and product information. Current product record; checked 6 September 2026.Autologous cartilage-cell medicine for selected knee defects. Its indication and rehabilitation pathway differ from general injections for osteoarthritis. Return to text ↑
- Mautner K, Gottschalk M, Boden SD, et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nature Medicine. 2023;29:3120–3126.MILES trial, 480 participants randomised. Three cell preparations did not show superior one-year primary pain outcomes versus corticosteroid injection. Return to text ↑
- Whittle SL, et al. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews. 2025;CD013342.Review published April 2025, with evidence searched to September 2023. Low certainty for slight pain and function benefits versus placebo; important uncertainties remain. Return to text ↑
- Cole BJ, Kaiser JT, Wagner KR, et al. Prospective Randomized Trial of Biologic Augmentation With Bone Marrow Aspirate Concentrate in Patients Undergoing Arthroscopic Rotator Cuff Repair. American Journal of Sports Medicine. 2023;51(5):1234–1242.Ninety-one participants randomised; 75 completed one-year MRI and 82 completed two-year clinical follow-up. Structural and patient-reported outcomes differed in their findings. Return to text ↑
- Sambasivan R, Yao R, Kissenpfennig A, et al. Pax7-expressing satellite cells are indispensable for adult skeletal muscle regeneration. Development. 2011;138(17):3647–3656.Experimental mouse research establishing a role for satellite cells in regeneration. It is not a trial of a marketed human muscle-repair treatment. Return to text ↑
- International Society for Stem Cell Research. The ISSCR Guide to Stem Cell Treatments. Patient and family guidance; accessed 6 September 2026.Guidance for understanding therapies, evidence and research safeguards. The article’s consultation framework is an original practical synthesis. Return to text ↑
- European Medicines Agency and Heads of Medicines Agencies. Unregulated advanced therapy medicinal products pose serious risks to health. Official communication. 13 March 2025.Explains EU supply pathways and concerns about unregulated products. National exemptions differ from central marketing authorisation. Return to text ↑
- World Anti-Doping Agency. The 2026 Prohibited List: International Standard. In force from 1 January 2026; checked 6 September 2026.M3 covers specified gene- and cell-based methods with potential to enhance sport performance. Other substances and methods may also affect treatment status. Return to text ↑
The most important breakthrough is a meaningful ability preserved or restored.
Genetic and cellular medicine can address problems that deserve more than today’s available answers. Its promise grows stronger when biological understanding is joined to careful treatment, useful rehabilitation and honest assessment.
Stay curious about what is becoming possible. Ask clear questions about what has been shown. Keep the person’s goals, choices and long-term well-being at the centre of the science.